Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.

Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G, Vassilopoulos D.

Ann Rheum Dis. 2015 Oct;74(10):1848-53. doi: 10.1136/annrheumdis-2014-205376. Epub 2014 May 22.

PMID:
24854354
2.

Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D.

Ann Rheum Dis. 2013 Feb;72(2):308-10. doi: 10.1136/annrheumdis-2012-202088. Epub 2012 Aug 28. No abstract available.

PMID:
22930597
3.

Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E.

Clin Vaccine Immunol. 2011 Dec;18(12):2102-8. doi: 10.1128/CVI.05299-11. Epub 2011 Oct 12.

Supplemental Content

Loading ...
Support Center